MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
Viveve Medical Accounts Receivables 2011-2026 | VIVE
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 549 K | 770 K | 1.57 M | 5.7 M | 6.21 M | 2.09 M | 593 K | 6 K | 502 K | 402 K | 453 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.21 M | 6 K | 1.71 M |
Quarterly Accounts Receivables Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 860 K | 801 K | 509 K | 549 K | 514 K | 696 K | 336 K | 770 K | 770 K | 770 K | 770 K | 1.57 M | 1.57 M | 1.57 M | 1.57 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 6.21 M | 6.21 M | 6.21 M | 6.21 M | 2.09 M | 2.09 M | 2.09 M | 2.09 M | 593 K | 593 K | 593 K | 593 K | 6 K | 6 K | 6 K | 6 K | 502 K | 488 K | 210 K | 502 K | 402 K | 402 K | 402 K | 402 K | 453 K | 453 K | 453 K | 453 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.21 M | 6 K | 1.64 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
AxoGen
AXGN
|
26.2 M | $ 28.6 | -1.92 % | $ 1.32 B | USA |
 |
Alphatec Holdings
ATEC
|
97.3 M | $ 12.19 | -3.02 % | $ 1.83 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
3.26 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
566 M | $ 36.62 | -4.9 % | $ 5.46 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
175 M | $ 8.63 | 2.92 % | $ 620 M |  Israel |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Cutera
CUTR
|
43.1 M | - | -10.19 % | $ 1.99 M | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 9.51 | -0.94 % | $ 1.29 B | USA |
 |
Electromed
ELMD
|
24.7 M | $ 24.0 | -1.56 % | $ 203 M | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 40.21 | -2.9 % | $ 1.25 B | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 4.21 | -0.94 % | $ 157 M |  France |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
Apyx Medical Corporation
APYX
|
14 M | $ 3.16 | -3.07 % | $ 109 M | USA |
 |
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
83.2 M | $ 0.49 | -2.39 % | $ 50.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.82 | 1.35 % | $ 44.6 M | USA |
 |
Align Technology
ALGN
|
996 M | $ 173.34 | -1.29 % | $ 13 B | USA |
 |
Butterfly Network
BFLY
|
20.8 M | $ 3.65 | -2.93 % | $ 773 M | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
7.93 B | $ 109.92 | -0.95 % | $ 191 B | USA |
 |
IRadimed Corporation
IRMD
|
10.6 M | $ 98.53 | -1.57 % | $ 1.25 B | USA |
 |
Inogen
INGN
|
38.9 M | $ 6.46 | -1.37 % | $ 172 M | USA |
 |
InMode Ltd.
INMD
|
10.5 M | $ 13.26 | -1.45 % | $ 857 M | Israel |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 18.05 | 1.29 % | $ 423 M | USA |
 |
IRIDEX Corporation
IRIX
|
6.73 M | $ 1.24 | -10.14 % | $ 20 M | USA |
 |
Pulmonx Corporation
LUNG
|
13.1 M | $ 2.03 | 25.78 % | $ 79.4 M | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 2.17 | -3.55 % | $ 1.32 M | USA |
 |
Medtronic PLC
MDT
|
6.52 B | $ 90.96 | -2.2 % | $ 117 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
660 M | $ 82.03 | -2.21 % | $ 48 B | USA |